ECSP22007557A - Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 - Google Patents
Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1Info
- Publication number
- ECSP22007557A ECSP22007557A ECSENADI20227557A ECDI202207557A ECSP22007557A EC SP22007557 A ECSP22007557 A EC SP22007557A EC SENADI20227557 A ECSENADI20227557 A EC SENADI20227557A EC DI202207557 A ECDI202207557 A EC DI202207557A EC SP22007557 A ECSP22007557 A EC SP22007557A
- Authority
- EC
- Ecuador
- Prior art keywords
- positive
- allesteric
- modulator
- tetrahydroisoquinoline derivative
- substituted tetrahydroisoquinoline
- Prior art date
Links
- 150000003526 tetrahydroisoquinolines Chemical class 0.000 title 1
- 230000003281 allosteric effect Effects 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente se refiere a compuestos de acuerdo con la fórmula (I), que son moduladores alostéricos positivos de D1 y, en consecuencia, son beneficiosos como agentes farmacéuticos para el tratamiento de enfermedades en las cuales los receptores D1 juegan un papel.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19183641 | 2019-07-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP22007557A true ECSP22007557A (es) | 2022-02-25 |
Family
ID=67137842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI20227557A ECSP22007557A (es) | 2019-07-01 | 2022-01-31 | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US12358890B2 (es) |
| EP (1) | EP3993795B1 (es) |
| JP (1) | JP7618597B2 (es) |
| KR (1) | KR102949226B1 (es) |
| CN (1) | CN114008032B (es) |
| AR (1) | AR119317A1 (es) |
| AU (1) | AU2020299705B2 (es) |
| BR (1) | BR112021022379A2 (es) |
| CA (1) | CA3139622A1 (es) |
| CL (1) | CL2021002949A1 (es) |
| CO (1) | CO2021017740A2 (es) |
| EC (1) | ECSP22007557A (es) |
| ES (1) | ES3069145T3 (es) |
| HR (1) | HRP20260599T1 (es) |
| IL (1) | IL289317B2 (es) |
| MA (1) | MA56445B1 (es) |
| MX (1) | MX2021015872A (es) |
| MY (1) | MY210362A (es) |
| PE (1) | PE20220373A1 (es) |
| PH (1) | PH12021552819A1 (es) |
| PL (1) | PL3993795T3 (es) |
| RS (1) | RS68243B1 (es) |
| SA (1) | SA521431274B1 (es) |
| SG (1) | SG11202112539XA (es) |
| TW (1) | TWI842923B (es) |
| UA (1) | UA130613C2 (es) |
| WO (1) | WO2021001286A1 (es) |
| ZA (1) | ZA202109194B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020131671A1 (en) | 2018-12-18 | 2020-06-25 | Eli Lilly And Company | Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders |
| EP4200280B1 (en) | 2020-10-07 | 2024-02-21 | Eli Lilly And Company | Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1 receptor positive allosteric modulators |
| CN117337173A (zh) * | 2021-03-09 | 2024-01-02 | 伊莱利利公司 | 美维达林和其他d1正向别构调节剂用于减缓帕金森氏病进展的用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010520217A (ja) | 2007-03-01 | 2010-06-10 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒスタミンｈ３受容体のモジュレーターとしてのテトラヒドロイソキノリン化合物 |
| KR101284796B1 (ko) | 2011-10-05 | 2013-07-10 | (주)포인트엔지니어링 | 캔 패지키 타입의 광 디바이스 제조 방법 및 이에 의해 제조된 광 디바이스 |
| US9278960B2 (en) | 2011-11-03 | 2016-03-08 | Merck Sharp & Dohme Corp. | Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use |
| JO3316B1 (ar) | 2013-05-30 | 2019-03-13 | Lilly Co Eli | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل |
| EA035544B1 (ru) | 2014-10-08 | 2020-07-03 | Юсб Байофарма Спрл | Производные тетрагидроизохинолина |
| CN108884050B (zh) * | 2016-04-13 | 2022-07-05 | Ucb生物制药私人有限公司 | 四氢异喹啉衍生物 |
| EP3596060B1 (en) * | 2017-03-16 | 2023-09-20 | F. Hoffmann-La Roche AG | New bicyclic compounds as atx inhibitors |
| TWI725408B (zh) | 2018-04-20 | 2021-04-21 | 美商美國禮來大藥廠 | 多巴胺d1受體正向異位調節劑 |
-
2020
- 2020-06-29 MX MX2021015872A patent/MX2021015872A/es unknown
- 2020-06-29 SG SG11202112539XA patent/SG11202112539XA/en unknown
- 2020-06-29 ES ES20735361T patent/ES3069145T3/es active Active
- 2020-06-29 CN CN202080043673.9A patent/CN114008032B/zh active Active
- 2020-06-29 PE PE2021002217A patent/PE20220373A1/es unknown
- 2020-06-29 PL PL20735361.6T patent/PL3993795T3/pl unknown
- 2020-06-29 JP JP2021575050A patent/JP7618597B2/ja active Active
- 2020-06-29 AU AU2020299705A patent/AU2020299705B2/en active Active
- 2020-06-29 RS RS20260706A patent/RS68243B1/en unknown
- 2020-06-29 US US17/621,871 patent/US12358890B2/en active Active
- 2020-06-29 MY MYPI2021006863A patent/MY210362A/en unknown
- 2020-06-29 EP EP20735361.6A patent/EP3993795B1/en active Active
- 2020-06-29 WO PCT/EP2020/068181 patent/WO2021001286A1/en not_active Ceased
- 2020-06-29 HR HRP20260599TT patent/HRP20260599T1/hr unknown
- 2020-06-29 BR BR112021022379A patent/BR112021022379A2/pt unknown
- 2020-06-29 MA MA56445A patent/MA56445B1/fr unknown
- 2020-06-29 UA UAA202106080A patent/UA130613C2/uk unknown
- 2020-06-29 IL IL289317A patent/IL289317B2/en unknown
- 2020-06-29 CA CA3139622A patent/CA3139622A1/en active Pending
- 2020-06-29 PH PH1/2021/552819A patent/PH12021552819A1/en unknown
- 2020-06-29 KR KR1020227002603A patent/KR102949226B1/ko active Active
- 2020-06-30 AR ARP200101852A patent/AR119317A1/es unknown
- 2020-06-30 TW TW109122034A patent/TWI842923B/zh active
-
2021
- 2021-11-08 CL CL2021002949A patent/CL2021002949A1/es unknown
- 2021-11-17 ZA ZA2021/09194A patent/ZA202109194B/en unknown
- 2021-12-23 CO CONC2021/0017740A patent/CO2021017740A2/es unknown
- 2021-12-30 SA SA521431274A patent/SA521431274B1/ar unknown
-
2022
- 2022-01-31 EC ECSENADI20227557A patent/ECSP22007557A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024015493A (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alosterico positivo de d1 | |
| UY35818A (es) | Composiciones y métodos para modular los receptores x farnesoides | |
| ECSP20033467A (es) | Compuestos macrocíclicos para tratar enfermedades | |
| CO2019010078A2 (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
| ECSP20021913A (es) | Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso | |
| UY33815A (es) | Composiciones y métodos para modular el fxr | |
| CO2021017740A2 (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 | |
| MX2018002326A (es) | Analogos novedosos de nucleosidos sustituidos en el anillo aromatico biciclico 6-6 para su uso como inhibidores de prmt5. | |
| CR20160119A (es) | Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística | |
| BR112016000909A8 (pt) | derivados piperidinil indólicos, seus usos, e combinação e composição farmacêuticas | |
| CU20140081A7 (es) | Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| UY35469A (es) | Moduladores de p2x7 | |
| DOP2015000054A (es) | Derivados de c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso | |
| MX2013006634A (es) | Compuestos de 2-amino-4-ariltiazol como antagonistas de trpa1. | |
| CU20140095A7 (es) | Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| ECSP17025302A (es) | N-alquilaril-5-oxiaril-octahidro ciclopenta[c]pirrol moduladores alostéricos negativos de nr2b | |
| CL2019003275A1 (es) | Derivados de pirimidina como moduladores del receptor de pge2. | |
| BR112017007123A2 (pt) | derivados de tetrahidroisoquinolina | |
| MX2019013639A (es) | Derivados de indol n-sustituidos. | |
| DOP2022000127A (es) | Triterpenoides sintéticos con sustituyentes a base de nitrógeno en c-17 y métodos de uso de los mismos. | |
| CO2022008308A2 (es) | Tieniloxazolonas y análogos | |
| UY36628A (es) | Indazolonas como moduladores de la señalización de tnf | |
| ECSP23041779A (es) | Un derivado de tetrahidroisoquinolina sustituido como un modulador alostérico positivo de d1 | |
| MX2019006517A (es) | Moduladores de ror gamma (rorv). |